Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

• ClinicalTrials.gov Identifier: NCT04389918
• Recruitment Status: Completed
• First Posted: May 15, 2020
• Last Update Posted: February 28, 2024
• Sponsor: Stanford University
• Collaborator: Filtricine Inc.
• Information provided by (Responsible Party): Stanford University

Study Description

Brief Summary:

This study will find out if a meal replacement of this type is satisfying and tolerable for men with prostate cancer. Participants will receive meal replacements of TalityTM as their expected sole source of nutrition for 4 weeks. The purpose of the study is to test whether TalityTM Synthetic Meal Replacements are suitable to be used in larger studies of patients with prostate or other types of cancer.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Other: Tality	Not Applicable

Detailed Description:

Primary Objective: Determine the appeal/tolerability/palatability of a diet consisting solely of TalityTM synthetic meal replacement in participants with prostate cancer Secondary Objective: Evaluate the effect of TalityTM on safety parameters including laboratory tests, nutritional status and adverse effects

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: A Phase I Study of the Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Patients With Prostate Cancer
• Actual Study Start Date: October 26, 2020
• Actual Primary Completion Date: February 26, 2024
• Actual Study Completion Date: February 26, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Tality; Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.	Other: Tality; Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.

Outcome Measures

Primary Outcome Measures :

1. Proportion of Completers [ Time Frame: 4 weeks ]
   The proportion of participants who complete the 4 week study using TalityTM as their sole source of nutrition at a high level of adherence (75% of days, 21+ days out of the 28 day study).

Secondary Outcome Measures :

1. Change in weight from baseline [ Time Frame: 4 weeks ]
   Change in weight will be measured from baseline.
2. Change in amino acid levels [ Time Frame: 4 weeks ]
   Change in amino acid levels as compared to baseline will be measured. The following amino acids will be analyzed a-Aminoadipic Acid, a-Aminobutyric Acid, Alanine, Arginine, Asparagine, Aspartic Acid, b-Alanine, b-Aminoisobutyric Acid, Citrulline, Cystathionine, Cystine, Ethanolamine, Glutamic Acid, Glutamine, Glycine, Histidine, Homocystine, Hydroxyproline, Isoleucine, Leucine, Lysine, Methionine, Ornithine, Phenylalanine, Proline, Sarcosine, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine. It will be measured in micro-moles per Liter.
3. Change in Prostate Specific Antigen [ Time Frame: 4 weeks ]
   Change from baseline in the serum level of prostate specific antigen (PSA).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Biopsy-proven prostate cancer with stable or rising PSA levels, defined as three consecutive PSA levels, each value greater than 1 week apart, with fluctuation between the three values no more than 10% downward. The third PSA needs to be within 30 days prior to enrollment and >= 0.1.
• Patients may previously have been on any regimen of chemotherapy completed at least one month prior. Patients may be on any stable form of anti-androgen therapy.
• Males >= age 18.
• All patients must have a life expectancy of > 6 months.
• Patients must have an ECOG Performance Status of <= 1
• Patients must have no clinically significant abnormalities of organ or bone marrow function
• Patients must have the ability to understand and the willingness to sign a written informed consent document, and the willingness/ability to comply with the protocol activities.

Exclusion Criteria:

• Chemotherapy within one month prior to enrollment or plans to receive chemotherapy within one month after enrollment. Patients who are expected to require new or modified anti-androgen therapy during the course of the study are also excluded.
• Patients may not be receiving any other Investigational Agents during the course of the study.
• Patients who experience frequent symptoms of a gastrointestinal nature (e.g., diarrhea, abdominal bloating, constipation or pain) are excluded.
• Known CNS metastases.
• Patients who, in the opinion of the Principal Investigator, have a clinically significant co-morbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes or result in adverse events unrelated to TalityTM are excluded.
• Patients with a history of food allergy are excluded.
• Concomitant medications necessary to treat baseline disorders are allowed (e.g., hypertension, diabetes, and hyperlipidemia).
• Patients requiring concomitant medications that, in the opinion of the Principal Investigator, have an unacceptable risk of adverse effects due to their nature (e.g., anti-coagulant therapy, immuno-modulatory agents for autoimmune disease) must be excluded.
• Pregnant or nursing patients will not be enrolled since prostate cancer is limited to males.
• HIV-positive patients with active infections, HIV related cancer or poorly controlled viral loads must be excluded. HIV-positive patients who are stable on anti-viral therapy may be enrolled.

Contacts and Locations

Locations

United States, California

Stanford University

Stanford, California, United States, 94304

Sponsors and Collaborators

Stanford University

Filtricine Inc.

Investigators

• Principal Investigator: Randall S Stafford, MD, PhD; Stanford Universiy

More Information

• Responsible Party: Stanford University
• ClinicalTrials.gov Identifier: NCT04389918
• Other Study ID Numbers: IRB-55337; PROS0100 ( Other Identifier: OnCore ); IRB-55337 ( Other Identifier: Stanford IRB )
• First Posted: May 15, 2020
• Last Update Posted: February 28, 2024
• Last Verified: February 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases